Indivior (INDV) said Thursday it expects $1.13 billion to $1.20 billion for 2026 net revenue, reflecting expected revenue growth from its Sublocade treatment for opioid use disorder.
Analysts polled by FactSet expect $1.13 billion.
The company said it expects Sublocade net revenue to increase by 11% in 2026, to between $905 million to $945 million, driven by dispense unit growth and expected margin expansion.
Shares of Indivior were up more than 1% in recent premarket activity Thursday.